Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | LPL | P06858 | 1/20 | 0.32 |
| ▸ | LIPC | P11150 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.32 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | AGXT | P21549 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3932476 | 0.83 | TACR1 (0.43) | SMYD2 | |
| SCHEMBL1853659 | 0.80 | AKR1B1 (0.34) | CYP3A4IDO1 | |
| SCHEMBL31385508 | 0.79 | MAPK1 (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL1314001 | 0.78 | AGXT (0.42) | SMYD2CYP3A4IDO1AGXT | |
| SCHEMBL14449078 | 0.78 | HTR1A (0.43) | CYP2C9CYP3A4 | |
| SCHEMBL501339 | 0.78 | TACR1 (0.32) | SMYD2CYP3A4 | |
| SCHEMBL3935879 | 0.76 | ESR1 (0.33) | — | |
| SCHEMBL29203398 | 0.74 | ACSS2 (0.35) | SMYD2 | |
| SCHEMBL30240876 | 0.74 | ACSS2 (0.35) | SMYD2 | |
| SCHEMBL31160327 | 0.74 | TOP2A (0.43) | NAMPTIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932271-B2 | Heterocyclic methyl sulfone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7932271-B2 | Heterocyclic methyl sulfone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20060241302-A1 | Morpholine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-10-26 | — | — | US | disclosed |
| EP-1640366-A1 | HETEROCYCLIC METHYL SULFONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241302-A1 | Morpholine derivatives | APP, BACE1, SMS | CYP11B1 29/4885CYP11B2 36/4885CYP2C9 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.